- Pulmotect Receives First Tranche of $8.9 Million from The State of Texas
- Pulmotect Awarded $8.9 Million from The State of Texas
- Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19
- Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19
- Pulmotect Appoints William J. Noss III as Chief Financial Officer
- Pulmotect Awarded Up To $6M From Department of Defense to Complete Two COVID-19 Trials
- Coronavirus protection drug approved by FDA for testing in Houston
KTRK ABC 13 - July 10, 2020 - Houston biotech company gets green light from FDA to test coronavirus-fighting drug
InnovationMap - May 2020 - Houston company testing drug to protect against COVID 19
KTRK-TV Houston - ABC 13 - May 2020 - Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19
- Houston company working on possible COVID-19 treatment
Houston Fox 26 News - March 2020 - Houston biotech co.’s coronavirus treatment candidate to undergo clinical trials
Houston Business Journal - March 2020 - Houston researchers test lung inhalant that could protect healthcare workers from COVID-19
Houston Chronicle - March 2020 - Pulmotect’s PUL-042 Shows Promising Pre-Clinical Efficacy in Preventing Lethal Coronavirus Infection
- Pulmotect Announces Initial Close on $12 Million Series B
- Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug
Scrip - June 2017 - Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
BioSpace - June 2017 - Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
- Pulmotect Convenes Inaugural Scientific Advisory Board
BioSpace - June 2017 - Pulmotect Convenes Inaugural Scientific Advisory Board